Literature DB >> 23636844

Sleep disturbance as part of the neurofibromatosis type 1 phenotype in adults.

Guy D Leschziner1, John F Golding, Rosalie E Ferner.   

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with a wide array of neurological complications, including cognitive dysfunction, tumors, malformations, neuropathy, neurovascular disease, and epilepsy. Many of these complications may impact on sleep quality and cause sleep disturbance. Previously sleep disturbance in NF1 has been specifically addressed solely in children. We performed a prospective study of sleep quality in 114 consecutive out-patients with NF1 attending our national neurofibromatosis service. The Epworth sleepiness scale (ESS) and the Pittsburgh sleep quality index (PSQI) were administered, and information was obtained from patient records on drugs potentially impacting on sleep, complications directly affecting sleep and employment status. The mean ESS was 6.8, and 21% had an abnormally high ESS of 10 or more. The mean global PSQI score was 8.4 (norm mean 2.67), with abnormally high scores in all sleep domains. Thirty-nine patients had a bed partner and 54% reported features suggestive of periodic limb movements of sleep, 43% had features suggestive of obstructive sleep apnoea, and 10.8% experienced confusion on waking. There was no evidence of phase shift. The ESS did not correlate with the PSQI, but unemployment status was associated with worse global PSQI score and multiple domain sub-scales of sleep quality in the PSQI. We conclude that sleep disturbance and poor sleep quality are significantly more frequent in the adult NF1 patient population. It is likely to be multi-factorial, related to pain, anxiety, depression, cognitive issues, and organic sleep pathology. We recommend careful assessment of patients to determine underlying triggers and possible treatment strategies.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23636844     DOI: 10.1002/ajmg.a.35915

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  13 in total

1.  The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.

Authors:  Ana-Maria Vranceanu; Vanessa L Merker; Scott R Plotkin; Elyse R Park
Journal:  J Neurooncol       Date:  2014-07-15       Impact factor: 4.130

2.  Health Survey of Adults with Neurofibromatosis 1 Compared to Population Study Controls.

Authors:  Krister W Fjermestad; Livø Nyhus; Øivind J Kanavin; Arvid Heiberg; Lise B Hoxmark
Journal:  J Genet Couns       Date:  2018-02-10       Impact factor: 2.537

Review 3.  Synaptic dysfunction connects autism spectrum disorder and sleep disturbances: A perspective from studies in model organisms.

Authors:  Fusun Doldur-Balli; Toshihiro Imamura; Olivia J Veatch; Naihua N Gong; Diane C Lim; Michael P Hart; Ted Abel; Matthew S Kayser; Edward S Brodkin; Allan I Pack
Journal:  Sleep Med Rev       Date:  2022-01-25       Impact factor: 11.401

4.  Neurofibromatosis type 1 (Nf1)-mutant mice exhibit increased sleep fragmentation.

Authors:  Corina Anastasaki; Nicholas Rensing; Kevin J Johnson; Michael Wong; David H Gutmann
Journal:  J Sleep Res       Date:  2019-01-04       Impact factor: 3.981

5.  Assessment of nociception and related quality-of-life measures in a porcine model of neurofibromatosis type 1.

Authors:  Rajesh Khanna; Aubin Moutal; Katherine A White; Aude Chefdeville; Pedro Negrao de Assis; Song Cai; Vicki J Swier; Shreya S Bellampalli; Marissa D Giunta; Benjamin W Darbro; Dawn E Quelle; Jessica C Sieren; Margaret R Wallace; Christopher S Rogers; David K Meyerholz; Jill M Weimer
Journal:  Pain       Date:  2019-11       Impact factor: 7.926

Review 6.  Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives.

Authors:  Gabriele Deidda; Ignacio F Bozarth; Laura Cancedda
Journal:  Front Cell Neurosci       Date:  2014-05-22       Impact factor: 5.505

7.  Neurofibromatosis type 1 and chronic neurological conditions in the United States: an administrative claims analysis.

Authors:  Chinwe C Madubata; Margaret A Olsen; Dustin L Stwalley; David H Gutmann; Kimberly J Johnson
Journal:  Genet Med       Date:  2014-06-05       Impact factor: 8.822

8.  Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Douglas R Stewart; Bruce R Korf; Katherine L Nathanson; David A Stevenson; Kaleb Yohay
Journal:  Genet Med       Date:  2018-04-26       Impact factor: 8.822

9.  Anaplastic Lymphoma Kinase Acts in the Drosophila Mushroom Body to Negatively Regulate Sleep.

Authors:  Lei Bai; Amita Sehgal
Journal:  PLoS Genet       Date:  2015-11-04       Impact factor: 5.917

10.  Abnormal circadian oscillation of hippocampal MAPK activity and power spectrums in NF1 mutant mice.

Authors:  Lei Chen; Tatiana Serdyuk; Beimeng Yang; Shuai Wang; Shiqing Chen; Xixia Chu; Xu Zhang; Jinjing Song; Hechen Bao; Chengbin Zhou; Xiang Wang; Shuangle Dong; Lulu Song; Fujun Chen; Guang He; Lin He; Ying Zhou; Weidong Li
Journal:  Mol Brain       Date:  2017-07-03       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.